Jan. 16 at 12:40 PM
$ALT The SP is going to stay in a tight trading range until two questions are answered. 1. How is MASH P3 being financed? ? Partnership? The great news is the science is strong, and ALT has received a nod from regulators (FDA) in the form of P3 alignment/BTD. Also MASH is not dominated by BP, and everyone wants to get in to this multi-billion dollar field. Off the top of my head I cant think of another independent small biotech that is this far along and checks off for commercialization with no titration, BIC safety and lean mass preservation. There will be many suitors, and the silence from ALT should be taken as a positive that a deal is getting done. Personally I think there will be a European deal. Earnings is generally around the third week of Feb, and thats when im rethinking we’ll get our answers on at least one of the two questions. No use stressing. Invest wisely
